@article{JGO23746,
author = {Sarah Walcott-Sapp and Scott Naugler and Jeong Youn Lim and Jesse Wagner and Susan L. Orloff and Khashayar Farsad and Kenneth J. Kolbeck and John Kaufman and Erin Maynard and C. Kristian Enestvedt and Skye C. Mayo and Kevin G. Billingsley},
title = {Tailored treatment of patients with hepatocellular carcinoma with portal vein invasion: experience from a multidisciplinary hepatobiliary tumor program within a NCI comprehensive cancer center},
journal = {Journal of Gastrointestinal Oncology},
volume = {9},
number = {6},
year = {2018},
keywords = {},
abstract = {Background: Hepatocellular carcinoma (HCC) with portal vein invasion (PVI) has a poor prognosis with limited treatment options. Intra-arterial brachytherapy (IAB) and transarterial chemoembolization (TACE) yield local control but risk accelerating liver dysfunction. The outcomes, survival, and safety of selective liver-directed treatment are reported.
Methods: Thirty-seven consecutive patients with HCC and PVI treated between 2009 and 2015 were reviewed from a prospectively collected database. Univariate analysis, Kaplan-Meier plots using the log-rank method, and multivariate analyses were performed. Statistical significance was defined as P},
issn = {2219-679X}, url = {https://jgo.amegroups.org/article/view/23746}
}